Solu Therapeutics is a biotechnology company dedicated to developing next-generation therapeutics to eliminate disease-driving cells in cancer, immunology and other therapeutic areas. The company’s proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTACTM (Therapeutic Index Control Targeting Chimera) platforms enable the development of innovative medicines that combine the target-binding capability of small molecules with the therapeutic power of biologics. Solu is committed to advancing the field of oncology, immunology and other therapeutic areas by bringing transformative therapies to patients in need.
Solu Therapeutics
Aer Therapeutics
Aer Therapeutics is a clinical-stage biopharmaceutical company dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases. The company's initial focus is chronic obstructive pulmonary disease (COPD) with other muco-obstructive lung diseases to follow, including asthma, cystic fibrosis, primary ciliary dyskinesia, and non–cystic fibrosis bronchiectasis.
Resilient Biotics
Resilient Biotics is utilizing advanced microbiome genomics and data science for prevention and precision treatment of deadly infectious diseases.
Enlaza Therapeutics
Enlaza Therapeutics is pioneering the field of covalent biologics. These novel classes of protein therapeutics deliver more efficacious and safer treatments for patients. The company’s proprietary War-LockTM platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza is building a pipeline of first-in-class covalent biologics.
Reactive Biosciences
Reactive Bioscience is using the world’s leading boron-based discovery platform to discover and develop medicines in innovative and imaginative new ways.
PharmAbbie
PharmAbbie is developing drugs targeted at the pet market based on existing human formulations. The company is concentrating on therapeutic categories including pain and inflammation, infections, diarrhea, dermatology, and cardiovascular problems, intended to provide safe, efficacious and easy-to-administer drugs to improve the quality of life of companion animals and their guardians.
Borah
Borah was formed in 2022 when the company Boragen was split into three separate companies, 5Metis, Borah and Reactive Biosciences.
Sorriso Pharmaceuticals
Sorriso is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the treatment of immune-mediated diseases, including Crohn’s disease and ulcerative colitis. The company's platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the human intestine.
RoboCT
RoboCT, a technology-driven enterprise, takes technology innovation as its core driving force and is committed to exoskeleton robot technology, robot core components and intelligent control technology. They focus on the fields of rehabilitation and elderly care through the combination of human-computer interaction technology, artificial intelligence technology, data analysis and cloud computing, providing intelligent products and solutions for medical and healthcare institutions and individual users.
Veralox Therapeutics
Veralox is a clinical stage company developing first-in-class small molecule therapeutics that treat the underlying pathologies of immuno-inflammatory diseases heparin-induced thrombocytopenia (HIT) and type 1 diabetes (T1D), as well as several programs in the discovery phase.
